Indaptus Therapeutics, Inc. (INDP)
| Market Cap | 138.16M +1,903.8% |
| Revenue (ttm) | n/a |
| Net Income | -18.86M |
| EPS | -5.27 |
| Shares Out | 113.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,297 |
| Open | 1.110 |
| Previous Close | 1.060 |
| Day's Range | 0.920 - 1.220 |
| 52-Week Range | 0.920 - 19.914 |
| Beta | 1.39 |
| Analysts | Buy |
| Price Target | 10.00 (+719.67%) |
| Earnings Date | May 15, 2026 |
About INDP
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for INDP stock is "Buy" and the 12-month stock price target is $10.0.
News
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the f...
Indaptus Therapeutics enters $6M securities purchase agreement with David Lazar
Indaptus Therapeutics (INDP) entered into a $6M securities purchase agreement with investor, David Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been ...
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics reports Q3 EPS ($2.98) vs ($9.04) last year
Jeffrey Meckler, Indaptus Therapeutics (INDP)’ Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and t...
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics provides update on INDP-D101 clinical trial
Indaptus Therapeutics (INDP) announced recent updates for the ongoing INDP-D101 clinical trial. “We currently have completed the monotherapy portion of our trial and have initiated seven patients in o...
Indaptus Therapeutics Provides Clinical Update
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with ...
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A.
Indaptus Therapeutics files to sell 781,250 shares of common stock, warrants
H.C. Wainwright & Co. is acting as exclusive placement agent in connection with this offering.
Indaptus Therapeutics files $200M mixed securities shelf
16:20 EDT Indaptus Therapeutics (INDP) files $200M mixed securities shelf
Indaptus Therapeutics files to sell 2.16M shares of common stock for holders
16:22 EDT Indaptus Therapeutics (INDP) files to sell 2.16M shares of common stock for holders
Indaptus Therapeutics reports Q2 EPS ($9.09) vs ($13.16) last year
Jeffrey Meckler, Indaptus Therapeutics (INDP)’ Chief Executive Officer, commented, “This quarter marks a major clinical inflection point for Indaptus. In under four years since our founding, we have p...
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical...
Indaptus Therapeutics announces additional sale of $3.4M in private placement
Indaptus Therapeutics (INDP) announced the additional sale of approximately $3.4M in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of...
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infectio...
Indaptus Therapeutics Inc trading resumes
10:05 EDT Indaptus Therapeutics (INDP) Inc trading resumes
Indaptus Therapeutics Inc trading halted, volatility trading pause
10:00 EDT Indaptus Therapeutics (INDP) Inc trading halted, volatility trading pause
Indaptus Therapeutics Inc trading halted, news pending
19:50 EDT Indaptus Therapeutics (INDP) Inc trading halted, news pending
Indaptus Therapeutics board approves 1-for-28 reverse stock split
Indaptus Therapeutics (INDP) announced that its Board of Directors has approved a one-for-twenty eight reverse stock split of its common stock that is scheduled to become effective after trading close...
Indaptus Therapeutics Announces Reverse Stock Split
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer a...
Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants
Indaptus Therapeutics (INDP) announced the sale of approximately $2.3M in aggregate principal amount of convertible promissory notes and accompanying warrants. This transaction is being led by a healt...
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infectio...
Indaptus doses first patient in Phase 1b.2 study of Decoy20 withTislelizumab
Indaptus Therapeutics (INDP) announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s PD-1 checkpoint inhibi...
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections,...